ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

STX Shield Therapeutics Plc

1.95
-0.10 (-4.88%)
21 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -4.88% 1.95 1.90 2.00 2.05 1.95 2.05 1,899,144 14:14:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.37 15.12M
Shield Therapeutics Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 2.05p. Over the last year, Shield Therapeutics shares have traded in a share price range of 1.075p to 12.75p.

Shield Therapeutics currently has 775,429,360 shares in issue. The market capitalisation of Shield Therapeutics is £15.12 million. Shield Therapeutics has a price to earnings ratio (PE ratio) of -0.37.

Shield Therapeutics Share Discussion Threads

Showing 4926 to 4949 of 23400 messages
Chat Pages: Latest  204  203  202  201  200  199  198  197  196  195  194  193  Older
DateSubjectAuthorDiscuss
08/1/2020
11:10
Think it’s just the upfront plus the milestones.
crankyman
08/1/2020
11:02
Cranky - it’s not quite clear what fincap have said vs what the rns states. Do you think it’s 63m plus royalities or 63m in potential max royalities (alongside the sales mile stones). One is clearly much better than the other.
Aside from that can someone remind me of the patent expiry for China?

2theduke
08/1/2020
10:06
So ASK will manufacturer too. It’s all gravy then for STX
crankyman
08/1/2020
10:03
Deal is being valued by finncap at $63 million plus trial costs. Sets it up for a >$50 million up front for the US
crankyman
08/1/2020
09:59
What is filling the gap?
crankyman
08/1/2020
09:58
This is just the starter to wet our appetite. It now puts STX in a position of power to negotiate terms in the US. The deal terms are bound to be lower in China with the partner covering all the regulatory costs. In the US it’s all done. I’d like to see this rise to 200p before the US deal drops
siriusbizness
08/1/2020
09:37
Paying above the offer for just 6k if stock. Bizarre price action this morning...
nobbygnome
08/1/2020
09:28
>> 74tom

Spot on with filling the gap and timing. That is a TA ‘rule’ which I never understand because I don’t see what would drive that behaviour. Ho hum at least it gave us a chance to top up at a low level!

nobbygnome
08/1/2020
09:23
117m shares in issue, volume today after this news, less than 200K...
growthinvestor2001
08/1/2020
09:15
Crazy reaction thought the chance to add had gone after this Mornings RNS amazing
best1467
08/1/2020
09:11
Some real mugging going on this morning NYboy. I too have taken advantage and added a few more.
nobbygnome
08/1/2020
09:08
Yes, couldn't agree more. It's like horse-racing in extended format!
daveboy1
08/1/2020
09:08
Adding a total of a other 10,000 shares after this news and dip, excellent stuff
ny boy
08/1/2020
09:04
We will most likely finish down, how corrupt is that. Sometimes you can only ask the question why do we invest in the stock market
sharestobuy
08/1/2020
09:01
I’d agree. I’d agree
crankyman
08/1/2020
08:59
Having now read through the full RNS my guess for upfront on the US deal is is in the region of $30/40 million any thoughts
best1467
08/1/2020
08:59
Having now read through the full RNS my guess for upfront on the US deal is is in the region of $30/40 million any thoughts
best1467
08/1/2020
08:58
The only thing investors are interested in is leveraging US price gouging. If you’ve got a positive phase 2 mab for advanced —-aloma you’re quids in. It will sky rocket. Meanwhile if you’re saving payors and treating a hugely prevalent disease with relatively simple technology, it’s like you’re selling a new toothpaste.
crankyman
08/1/2020
08:51
But people have been selling recently so that adage doesn’t really hold in this case!

The market is mad as always. Patience is a virtue; this was only the appetiser...

nobbygnome
08/1/2020
08:50
As said before, iron deficiency is hugely prevalent in China. The potential for Feraccru is enormous because it’s the kind of drug that can do well in a largely self pay system. You can’t sell orphan oncology there. Fantastic that they sealed it and things can move forward. Slightly nonplussed on the margin but hey ho, it’s a market place and that’s the price. No point hanging around. As mentioned, ASK pays for the trials and there are some nice milestones. In the end, they’ll invest more if they are taking 85% so it should end up net positive compared to a higher margin. Clearly I was hoping for a better up front. Still, some nice pocket money to keep the company going for another 6 months. Takes it completely out of danger of needing to raise cash. I still don’t expect it to rise. This market doesn’t believe. It won’t till it sees cash rolling in.
crankyman
08/1/2020
08:43
Sell on news - buy on rumour
red army
08/1/2020
08:41
Dont hold your breath 74.....its gapping down not up
luisfrg
08/1/2020
08:38
Filling the gap up, will rise post 9am IMO.
74tom
08/1/2020
08:36
Madness can see this ending the day flat...
luisfrg
Chat Pages: Latest  204  203  202  201  200  199  198  197  196  195  194  193  Older

Your Recent History

Delayed Upgrade Clock